Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

EGFR tri-specific natural killer cell engager DF9001

A tri-specific natural killer (NK) cell engager targeting epidermal growth factor receptor (EGFR), with potential immunostimulating and antineoplastic activities. Upon administration, EGFR tri-specific NK cell engager DF9001 targets and binds to EGFR on tumor cells and simultaneously binds to NK cells, thereby bringing EGFR-expressing tumor cells and NK cells together. This stimulates the NK cells and results in the selective NK cell-mediated killing of EGFR-expressing tumor cells. In addition, the NK cells activate T- and B-cells, and enhance a cytotoxic T-lymphocyte (CTL)-mediated immune response against EGFR-expressing tumor cells. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.
Synonym:EGFR tri-specific NK cell engager DF9001
EGFR-targeting tri-specific NK cell engager DF9001
TriNKET DF9001
Code name:DF 9001
DF-9001
DF9001
Search NCI's Drug Dictionary